Evolus Future Growth
Future criteria checks 5/6
Evolus is forecast to grow earnings and revenue by 74% and 24.3% per annum respectively while EPS is expected to grow by 73.5% per annum.
Key information
74.0%
Earnings growth rate
73.5%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 24.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 16 Dec 2024 |
Recent future growth updates
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results
May 10The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 10Recent updates
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%
Nov 13Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?
Oct 22Evolus Continues To Make Progress
Aug 02Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump
Aug 02Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt
Jul 13Evolus: Chiseling Away At The Aesthetic Market
May 22Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results
May 10Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
Mar 20The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 10Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Jan 18Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up
Jan 18Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?
Jun 16Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?
Nov 06Evolus concludes certain royalty payments related to settlement of IP rights dispute
Sep 21Evolus: Turning That Frown Upside Down
Sep 11Evolus appoints Experian's exec as CFO
Aug 30Is Evolus (NASDAQ:EOLS) Using Too Much Debt?
Aug 04Evolus Q2 2022 Earnings Preview
Aug 01Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?
Mar 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 459 | 16 | 47 | 80 | 6 |
12/31/2025 | 347 | -26 | -10 | 16 | 6 |
12/31/2024 | 264 | -49 | -15 | 9 | 6 |
9/30/2024 | 248 | -55 | -26 | -22 | N/A |
6/30/2024 | 237 | -53 | -20 | -17 | N/A |
3/31/2024 | 220 | -60 | -26 | -24 | N/A |
12/31/2023 | 202 | -62 | -36 | -34 | N/A |
9/30/2023 | 185 | -63 | -46 | -44 | N/A |
6/30/2023 | 169 | -66 | -63 | -60 | N/A |
3/31/2023 | 156 | -72 | -70 | -67 | N/A |
12/31/2022 | 149 | -74 | -88 | -85 | N/A |
9/30/2022 | 140 | -79 | -87 | -85 | N/A |
6/30/2022 | 132 | -79 | -101 | -100 | N/A |
3/31/2022 | 121 | -71 | -64 | -63 | N/A |
12/31/2021 | 100 | -47 | -34 | -33 | N/A |
9/30/2021 | 86 | -139 | -27 | -27 | N/A |
6/30/2021 | 77 | -131 | -10 | -8 | N/A |
3/31/2021 | 58 | -137 | -40 | -38 | N/A |
12/31/2020 | 57 | -163 | -61 | -58 | N/A |
9/30/2020 | 55 | -67 | -76 | -72 | N/A |
6/30/2020 | 51 | -82 | -87 | -83 | N/A |
3/31/2020 | 45 | -99 | -107 | -102 | N/A |
12/31/2019 | 35 | -90 | -98 | -93 | N/A |
9/30/2019 | 15 | -88 | -93 | -89 | N/A |
6/30/2019 | 2 | -73 | -73 | -70 | N/A |
3/31/2019 | N/A | -52 | -43 | -43 | N/A |
12/31/2018 | N/A | -47 | -26 | -26 | N/A |
9/30/2018 | N/A | -30 | -15 | -15 | N/A |
6/30/2018 | N/A | -21 | N/A | -12 | N/A |
3/31/2018 | N/A | -7 | N/A | -10 | N/A |
12/31/2017 | N/A | -4 | N/A | -13 | N/A |
9/30/2017 | N/A | -13 | N/A | -14 | N/A |
6/30/2017 | N/A | -14 | N/A | -13 | N/A |
3/31/2017 | N/A | -18 | N/A | -14 | N/A |
12/31/2016 | N/A | -20 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EOLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: EOLS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EOLS is expected to become profitable in the next 3 years.
Revenue vs Market: EOLS's revenue (24.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: EOLS's revenue (24.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EOLS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/29 03:10 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evolus, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Balaji Prasad | Barclays |
Balaji Prasad | Barclays |
Navann Ty Dietschi | BNP Paribas Exane |